Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Edgewise Therapeutics Inc

Healthcare US EWTX

37.33USD
1.12(3.09%)

Last update at 2026-06-04T17:47:00Z

Day Range

35.9938.00
LowHigh

52 Week Range

12.1535.00
LowHigh

Fundamentals

  • Previous Close 36.21
  • Market Cap3643.98M
  • Volume306414
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-189.32200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.63

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -167.79500M -133.81300M -100.16300M -19.41500M -42.81300M
Minority interest - - - - -
Net income -167.79500M -133.81300M -100.16300M -15.39700M -42.13900M
Selling general administrative 40.02M 31.87M 23.45M 5.47M 11.03M
Selling and marketing expenses - - 0.18M - -
Gross profit -2.26600M -2.29000M -1.73200M - -
Reconciled depreciation 2.27M 2.29M 1.73M 0.54M 0.27M
Ebit -167.79500M -158.83200M -114.35700M -22.61700M -43.48700M
Ebitda -165.52900M -156.54200M -112.62500M -22.07900M -43.21500M
Depreciation and amortization 2.27M 2.29M 1.73M 0.54M 0.27M
Non operating income net other - - - 4.02M 0.40M
Operating income -191.40600M -158.83200M -114.35700M -22.07900M -43.21500M
Other operating expenses 191.41M 158.83M 114.36M 22.08M 43.22M
Interest expense - - - 4.02M 0.27M
Tax provision - - - - -
Interest income 23.61M 25.02M 14.19M 4.02M 0.40M
Net interest income 23.61M 25.02M 14.19M 4.02M 0.40M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.00000M - -4.01800M -0.67400M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 189.14M 158.83M 114.36M 22.08M 43.22M
Cost of revenue 2.27M 2.29M 1.73M - -
Total other income expense net 23.61M 25.02M 14.19M 2.66M 0.40M
Discontinued operations - - - - -
Net income from continuing ops -167.79500M -133.81300M -100.16300M -67.64000M -42.81300M
Net income applicable to common shares - - - -67.64000M -42.81300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 552.60M 486.82M 340.04M 367.10M 285.23M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.28M 5.31M 8.60M 5.05M 2.98M
Total liab 30.35M 27.60M 21.20M 20.39M 10.85M
Total stockholder equity 522.26M 459.22M 318.83M 346.72M 274.38M
Deferred long term liab - - - 0.25M -
Other current liab 20.35M 17.29M 11.77M 9.87M 6.68M
Common stock 0.01000M 0.00900M 0.00700M 0.00600M 0.00500M
Capital stock 0.01000M 0.00900M 0.00700M 0.00600M 0.00500M
Retained earnings -546.37100M -378.57600M -244.76300M -144.60000M -76.96000M
Other liab - - - - 0.33M
Good will - - - - -
Other assets - - - 0.25M 0.55M
Cash 61.15M 41.67M 86.10M 351.95M 280.79M
Cash and equivalents - - - - -
Total current liabilities 27.37M 23.86M 16.77M 16.59M 10.52M
Current deferred revenue - - - - -
Net debt -57.15800M -36.92900M -80.68300M -347.53900M -280.78900M
Short term debt 1.01M 1.00M 0.98M 0.61M -
Short long term debt - - - - -
Short long term debt total 3.99M 4.74M 5.41M 4.41M -
Other stockholder equity 1067.94M 837.36M 563.49M 492.67M 66.62M
Property plant equipment - - - 8.53M 0.91M
Total current assets 543.38M 475.48M 327.00M 351.95M 280.79M
Long term investments - - - - -
Net tangible assets - - - 346.72M 274.38M
Short term investments 468.96M 428.50M 232.30M 329.95M 265.22M
Net receivables - - - 0.25M 0.55M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 6.01M 5.58M 4.03M 6.11M 3.84M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.68M 0.42M 0.10M -1.35500M -0.51400M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00600M 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -144.60000M -76.96000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.26M 0.35M 5.30M 3.53M
Deferred long term asset charges - - - - -
Non current assets total 9.22M 11.33M 13.04M 15.15M 4.44M
Capital lease obligations 3.99M 4.74M 5.41M 4.41M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -32.53400M -184.65600M 0.31M -70.57700M -241.55900M
Change to liabilities - - - 2.62M 7.02M
Total cashflows from investing activities -32.79000M -184.65600M 102.89M -70.57700M -242.22700M
Net borrowings - - - -0.25100M -
Total cash from financing activities 196.09M 249.25M 53.17M 129.64M 186.38M
Change to operating activities - - - 4.04M 1.98M
Net income -167.79500M -133.81300M -100.16300M -67.64000M -42.81300M
Change in cash 19.48M -44.43100M 64.10M 6.43M -89.35000M
Begin period cash flow 41.67M 86.10M 21.99M 15.57M 104.92M
End period cash flow 61.15M 41.67M 86.10M 21.99M 15.57M
Total cash from operating activities -143.81600M -109.02800M -91.94800M -52.63500M -33.50700M
Issuance of capital stock 187.36M 239.15M -0.55500M 129.16M 186.15M
Depreciation 2.27M 2.29M 1.73M 0.54M 0.27M
Other cashflows from investing activities -32.79000M - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 129.89M 186.38M
Other cashflows from financing activities 196.09M 10.11M 0.55M 0.47M 0.24M
Change to netincome - - - 10.92M 4.40M
Capital expenditures 0.26M 1.31M 5.75M 5.55M 0.67M
Change receivables - - - - -
Cash flows other operating - - - 1.64M -2.39200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 6.43M -89.35000M
Change in working capital -5.37400M 10.33M -1.56000M 4.09M 4.63M
Stock based compensation 34.75M 24.71M 17.56M 10.92M 4.40M
Other non cash items 27.09M -12.54500M -9.51700M -0.54300M -228.94500M
Free cash flow -143.81600M -110.34000M -97.69300M -58.18100M -34.17500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EWTX
Edgewise Therapeutics Inc		 1.12 3.09% 37.33 - - - 6.98 -2.6031
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics Inc

1715 38th Street, Boulder, CO, United States, 80301

Key Executives

Name Title Year Born
Dr. Kevin Koch Ph.D. Pres, CEO & Director 1960
Dr. Badreddin Edris Ph.D. Co-Founder & Independent Director 1987
Dr. Behrad Derakhshan Ph.D. Chief Bus. Officer 1980
Dr. Joanne M. Donovan M.D., Ph.D. Chief Medical Officer 1957
Dr. Alan J. Russell Ph.D. Co-Founder, Chief Scientific Officer & Director 1970
Mr. R. Michael Carruthers Chief Financial Officer 1958
Mr. John R. Moore Gen. Counsel 1964
Dr. Peter A. Thompson FACP, M.D. Co-Founder & Independent Chairman 1960
Dr. Kevin Koch Ph.D. President, CEO & Director 1960
Dr. Badreddin Edris Ph.D. Co-Founder & Independent Director 1988

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.